Myalgic encephalomyelitis/chronic fatigue syndrome

Myalgic encephalomyelitis/chronic fatigue syndrome
Other namesPost-viral fatigue syndrome (PVFS), systemic exertion intolerance disease (SEID)[1]: 20 
Icons of the four key ME/CFS symptoms: low battery for profound fatigue, weak muscle for post-exertional malaise, bed for sleep problems and crossed wires in brain for cognitive difficulties.
The four primary symptoms of ME/CFS according to the National Institute for Health and Care Excellence
SpecialtyRheumatology, rehabilitation medicine, endocrinology, infectious disease, neurology, immunology, general practice, paediatrics, other specialists in ME/CFS[2]: 58 
SymptomsWorsening of symptoms with activity, long-term fatigue, sleep problems, others[3]
Usual onsetPeaks at 10–19 and 30–39 years old[4]
DurationLong-term[5]
CausesUnknown[6]
Risk factorsBeing female, family history, viral infections[6]
Diagnostic methodBased on symptoms[7]
TreatmentSymptomatic[8]
PrevalenceAbout 0.17% to 0.89% (pre-pandemic)[9]

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a serious long-term illness. People with ME/CFS experience a profound fatigue that does not go away with rest, sleep issues and problems with memory or concentration. They are able to do much less than before they became ill. Further common symptoms include dizziness, nausea and pain.[3] The hallmark symptom is a worsening of the illness hours to days after minor physical or mental activity. This "crash" can last less than a day to several months.[10]

The cause or causes of the disease are unknown.[11] ME/CFS often starts after an infection, such as mononucleosis.[12] ME/CFS can run in families, but the genes that contribute to ME/CFS risk are not known.[13] ME/CFS is associated with changes in the nervous and immune systems, as well as in energy production.[14] Diagnosis is based on symptoms because no diagnostic test is available.[7]

The illness can improve or worsen over time, but full recovery is uncommon.[12] Treatment is aimed at relieving symptoms, as no therapies or medications are approved to treat the condition.[2]: 29  Pacing one's activities can help avoid flare-ups and counselling may help in coping with the illness.[8] Before the COVID-19 pandemic, ME/CFS affected roughly one in every 150 people, although estimates varied widely.[9] However, many people with long COVID fit ME/CFS diagnostic criteria.[15] ME/CFS occurs more often in women than in men. It most commonly affects adults between ages 40 and 60 but can occur at other ages, including childhood.[16]

ME/CFS has a large social and economic impact. About a quarter of individuals are severely affected and unable to leave their bed or home.[10]: 3  The disease can be socially isolating.[17] People with ME/CFS often face stigma in healthcare settings and care is complicated by controversies around the cause and treatments of the illness.[18] Doctors may be unfamiliar with ME/CFS, as it is often not covered in medical school.[15] Historical research funding for ME/CFS has been far below that of diseases with comparable impact.[19]

  1. ^ Cite error: The named reference IOM2015 was invoked but never defined (see the help page).
  2. ^ a b "Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management: NICE guideline". National Institute for Health and Care Excellence (NICE). 29 October 2021. Archived from the original on 8 February 2024. Retrieved 9 March 2024.
  3. ^ a b "Symptoms of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome". U.S. Centers for Disease Control and Prevention (CDC). 10 May 2024. Archived from the original on 17 May 2024. Retrieved 17 May 2024.
  4. ^ Cite error: The named reference pmid31379194 was invoked but never defined (see the help page).
  5. ^ "Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management: Information for the public". National Institute for Health and Care Excellence (NICE). 29 October 2021. Archived from the original on 4 April 2024. Retrieved 24 March 2024.{{cite web}}: CS1 maint: bot: original URL status unknown (link)
  6. ^ a b Cite error: The named reference pmid37793728 was invoked but never defined (see the help page).
  7. ^ a b Cite error: The named reference pmid37226227 was invoked but never defined (see the help page).
  8. ^ a b "Manage Myalgic Encephalomyelitis/Chronic Fatigue Syndrome". U.S. Centers for Disease Control and Prevention (CDC). 10 May 2024. Archived from the original on 18 May 2024. Retrieved 18 May 2024.
  9. ^ a b Lim EJ, Ahn YC, Jang ES, Lee SW, Lee SH, Son CG (February 2020). "Systematic review and meta-analysis of the prevalence of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME)". Journal of Translational Medicine. 18 (1): 100. doi:10.1186/s12967-020-02269-0. PMC 7038594. PMID 32093722.
  10. ^ a b Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) (17 April 2023). Myalgische Enzephalomyelitis / Chronic Fatigue Syndrome (ME/CFS): Aktueller Kenntnisstand [Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): current state of knowledge] (PDF) (in German). Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. ISSN 1864-2500. Archived (PDF) from the original on 2 November 2023. Retrieved 8 November 2023.
  11. ^ Cite error: The named reference CDC_Clinical2024 was invoked but never defined (see the help page).
  12. ^ a b Bateman L, Bested AC, Bonilla HF, Chheda BV, Chu L, Curtin JM, et al. (November 2021). "Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Essentials of Diagnosis and Management". Mayo Clinic Proceedings. 96 (11): 2861–2878. doi:10.1016/j.mayocp.2021.07.004. PMID 34454716. S2CID 237419583.{{cite journal}}: CS1 maint: overridden setting (link)
  13. ^ Dibble JJ, McGrath SJ, Ponting CP (September 2020). "Genetic risk factors of ME/CFS: a critical review". Human Molecular Genetics. 29 (R1): R117–R124. doi:10.1093/hmg/ddaa169. PMC 7530519. PMID 32744306.
  14. ^ Annesley SJ, Missailidis D, Heng B, Josev EK, Armstrong CW (March 2024). "Unravelling shared mechanisms: insights from recent ME/CFS research to illuminate long COVID pathologies". Trends in Molecular Medicine. 30 (5): 443–458. doi:10.1016/j.molmed.2024.02.003. PMID 38443223.
  15. ^ a b Davis HE, McCorkell L, Vogel JM, Topol EJ (March 2023). "Long COVID: major findings, mechanisms and recommendations". Nature Reviews. Microbiology. 21 (3): 133–146. doi:10.1038/s41579-022-00846-2. PMC 9839201. PMID 36639608.
  16. ^ "Epidemiology". Centers for Disease Control and Prevention (CDC). 21 March 2023. Archived from the original on 6 March 2024. Retrieved 13 April 2024.
  17. ^ Shortland D, Fazil Q, Lavis A, Hallett N (4 April 2024). "A systematic scoping review of how people with ME/CFS use the internet". Fatigue: Biomedicine, Health & Behavior. 12 (2): 142–176. doi:10.1080/21641846.2024.2303887. ISSN 2164-1846.
  18. ^ O'Leary D (December 2020). "A concerning display of medical indifference: reply to 'Chronic fatigue syndrome and an illness-focused approach to care: controversy, morality and paradox'". Medical Humanities. 46 (4): e4. doi:10.1136/medhum-2019-011743. PMID 32601171. S2CID 220253462.
  19. ^ Tyson S, Stanley K, Gronlund TA, Leary S, Emmans Dean M, Dransfield C, et al. (2022). "Research priorities for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): the results of a James Lind alliance priority setting exercise". Fatigue: Biomedicine, Health & Behavior. 10 (4): 200–211. doi:10.1080/21641846.2022.2124775. ISSN 2164-1846. S2CID 252652429.{{cite journal}}: CS1 maint: overridden setting (link)

© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search